SEOUL, South Korea, Feb. 13, 2025 /CNW/ -- Hanmi Pharmaceutical's Global Business Headquarters Overseas Sales Team is making ...

Then, in January, the FDA approved the company's drug Omvoh for Crohn's disease. The drug was first approved in October 2023 for patients with moderately to severely active ulcerative colitis ...

A 5-year-old boy died in an explosion at a medical facility in Troy, Mich., on Friday, Jan. 31, according to the Troy Fire Department. The young child, whose identity has not been revealed, was in a ...

EXTON, PA, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The FDA's approval of Eli Lilly’s Omvoh for Crohn’s disease marks a significant milestone as the therapy becomes the second IL-23 inhibitor ...

FRANKFURT (Reuters) - The American CEO of Swiss drugmaker Novartis on Friday warned that the United States' exit from the World Health Organization and related programmes risks harming millions of ...

Omvoh (mirikizumab-mrkz) has potential interactions with certain vaccines and health conditions. These interactions could cause harmful effects in some people. Omvoh is used in adults to treat ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Wearable devices can identify ...

The senior vice president at Lilly Immunology Development discusses recent developments with Omvoh. The European Medicines Agency’s Committee for Medicinal Products for Human Use recently issued a ...

Use your computer. The checklist may not open on tablets or mobile phones. For most Internet browsers, clicking on the link above will ask you what you would like to do with the checklist.

BeyondSpring (BYSI) has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED Therapeutics for gross proceeds of approximately $35.4M. Upon completion of ...

The recent approval of Omvoh for Crohn's disease, following its success in ulcerative colitis, demonstrates Eli Lilly's commitment to broadening its therapeutic reach. One of the key challenges ...